Drawing for CLEARCHO

USPTO serial 99878692

CLEARCHO

Reviewed by CopyMark Law Group

Status 647Office Action
Filing date
Status date
Registration date
—
Examiner
BERGER, MAGDALENA
Law office
TMO LAW OFFICE 123

What this means

The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.

Need help with CLEARCHO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

F. Michael Sajovec

F. Michael Sajovec Williams Mullen301 Fayetteville Street, Suite 1700c/o IP DocketRaleigh, NC 27601

Goods and services

ClassDescriptionStatusFirst use
001Biological preparations, namely, Chinese hamster ovary (CHO) cell lines used for the production of biotherapeuticsACTIVE—
005Biological preparations for use in cell cultures for medical purposes, namely, Chinese hamster ovary (CHO) cell lines used to generate proteins for medical purposes in the nature of recombinant proteins for human and other mammalian useACTIVE—
042Cell line development for othersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 4, 2026GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 4, 2026XAECEXAMINER'S AMENDMENT ENTERED—
Nov 4, 2026GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 4, 2026CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 28, 2026DOCKASSIGNED TO EXAMINER—
Oct 27, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 11, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 11, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance